Clinical trialPhase 3Completed
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- 29 October 2001
- Expected end
- 10 February 2009
- Enrollment
- 569 participants
- Sites
- 173
- Primary outcomes
- Overall survival
- Sponsor
- Network
- Results posted
- No
- Last update
- 2 April 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 1
- Registry-listed results paperErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III tri… DOI 10.1200/jco.2006.07.9525↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.